US Physical Therapy EVP Binstein Sells 2,000 Shares at $84.79/Share.
ByAinvest
Tuesday, Aug 19, 2025 5:51 pm ET1min read
USPH--
The filing highlights that most of Binstein's holdings (15,726 shares) are restricted and subject to a staggered vesting schedule through 2029, which limits near-term liquidity of those shares. The transaction itself appears routine and is documented via Form 4; no convertible or derivative transactions are reported. For investors tracking insider activity, the sale is a data point but the substantial restricted position indicates continued alignment with the company via time-based vesting [1].
Analysts have been optimistic about USPH, with the iShares U.S. Healthcare Providers ETF (Symbol: IHF) having an implied analyst target price of $109.67 per share, representing a 23.89% upside from the recent price of $88.52 [2]. This optimism is reflected in the company's valuation metrics, with a forward P/E ratio of 33.65 and a PEG ratio of 4.40, suggesting that analysts believe in the company's future growth prospects [3].
In summary, while the insider sale is a routine event, it provides investors with a snapshot of the company's insider activity. The substantial restricted position held by Binstein indicates a long-term commitment to the company, while the analyst targets suggest optimism about USPH's future performance.
References:
[1] https://www.stocktitan.net/sec-filings/USPH/form-4-us-physical-therapy-inc-insider-trading-activity-c6598ef96b17.html
[2] https://www.nasdaq.com/articles/analysts-see-16-gains-ahead-holdings-ihf
[3] https://www.nasdaq.com/articles/asth-or-usph-which-better-value-stock-right-now
US Physical Therapy Inc /NV [USPH] has announced that EVP General Counsel & Secretary, Binstein Richard, has sold 2000 shares at a price of $84.79 per share on August 19, 2025.
US Physical Therapy Inc. /NV [USPH] has recently disclosed that EVP General Counsel & Secretary, Richard Binstein, sold 2,000 shares of the company's stock on August 19, 2025, at a price of $84.79 per share. The transaction, filed under SEC Form 4, represents a modest block of shares, reducing Binstein's direct holdings to 17,867 shares [1].The filing highlights that most of Binstein's holdings (15,726 shares) are restricted and subject to a staggered vesting schedule through 2029, which limits near-term liquidity of those shares. The transaction itself appears routine and is documented via Form 4; no convertible or derivative transactions are reported. For investors tracking insider activity, the sale is a data point but the substantial restricted position indicates continued alignment with the company via time-based vesting [1].
Analysts have been optimistic about USPH, with the iShares U.S. Healthcare Providers ETF (Symbol: IHF) having an implied analyst target price of $109.67 per share, representing a 23.89% upside from the recent price of $88.52 [2]. This optimism is reflected in the company's valuation metrics, with a forward P/E ratio of 33.65 and a PEG ratio of 4.40, suggesting that analysts believe in the company's future growth prospects [3].
In summary, while the insider sale is a routine event, it provides investors with a snapshot of the company's insider activity. The substantial restricted position held by Binstein indicates a long-term commitment to the company, while the analyst targets suggest optimism about USPH's future performance.
References:
[1] https://www.stocktitan.net/sec-filings/USPH/form-4-us-physical-therapy-inc-insider-trading-activity-c6598ef96b17.html
[2] https://www.nasdaq.com/articles/analysts-see-16-gains-ahead-holdings-ihf
[3] https://www.nasdaq.com/articles/asth-or-usph-which-better-value-stock-right-now
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet